hVIVO Beats EBITDA Guidance as Acquisitions Cement Full-Service CRO Platform

The latest update is out from Open Orphan Plc ( (GB:HVO) ).

hVIVO reported that 2025 revenue is expected to come in at about £46.7 million, in line with guidance but down from the prior year, while delivering a better-than-anticipated low single-digit positive adjusted EBITDA margin and maintaining a debt-free balance sheet with £14.3 million in cash, despite significant outlays on acquisitions. Management said the completed integration of CRS Mannheim & Kiel and Cryostore has transformed the group into an integrated, four-line service platform spanning consulting, clinical trials, human challenge trials and laboratory services, broadening its therapeutic reach beyond infectious diseases into cardiometabolic, respiratory and immunology, and underpinning reiterated guidance for high single-digit revenue growth in 2026 amid an improving pipeline and signs of recovery in the infectious disease market.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £7.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on GB:HVO Stock

According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.

Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.

To see Spark’s full report on GB:HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a full-service early phase contract research organisation (CRO) and the global leader in human challenge clinical trials, providing end-to-end drug development services from preclinical through Phase II and Phase III support. The company specialises in infectious and respiratory disease studies via its large quarantine facility in London, while its German CRS subsidiary offers early-phase clinical trial services and its Venn Life Sciences arm provides early drug development consulting and biometry. hVIVO also runs comprehensive virology and immunology laboratories under the hLAB brand, operates five clinical sites and the FluCamp recruitment platform, and serves a diverse client base that includes seven of the world’s ten largest biopharma companies.

Average Trading Volume: 4,645,475

Technical Sentiment Signal: Sell

Current Market Cap: £40.53M

For a thorough assessment of HVO stock, go to TipRanks’ Stock Analysis page.